Orakl Oncology

📣 📣 France Biotech et son groupe d’expertise “IA & Biodiscovery” publient une cartographie des modèles d’affaires des sociétés de TechBio françaises  Dans le cadre de son travail pour mieux comprendre les modèles économiques des sociétés utilisant l'intelligence artificielle pour la découverte de nouveaux médicaments, le groupe d’expertise « IA & Biodiscovery » de la commission Business Développement de France Biotech a récemment réalisé une cartographie des entreprises du secteur 🔎 Ces résultats ont été présentés lors de l’événement TechBio 2024 le 20 novembre dernier, organisé par WhiteLab Genomics en partenariat avec AI for Health, France Biotech, France Deeptech et Future4Care   Que retenir de l’étude ?  ➡️ Les entreprises TechBio (une vingtaine en France) se concentrent principalement sur le développement d’actifs propriétaires ➡️ Elles visent à étendre leurs activités vers des wet labs (en plus de labos in silico), en interne ou à travers des partenariats ➡️ L'oncologie émerge comme le domaine thérapeutique principal  ➡️ L'accès aux données de santé publiques françaises constitue un élément clé pour ces sociétés ➡️ Les partenariats universitaires sont importants pour le scale-up des entreprises  ➡️ Les levées de fonds récentes ont principalement servi à développer des plateformes et à acquérir des données Découvrez la publication complète sur le site de France Biotech 📄 > https://lnkd.in/eSFN7WpA 🙏 Un grand merci aux membres du groupe d’expertise “IA & Biodiscovery” pour ces réflexions et le travail réalisé : Antonio V Borderia Giner, Sarah Cordelle,Timothé CYNOBER (Pharm D.), Chloe Evans, Fanny Goretta, Mathieu Losguardi, Marie Meier et Diane-Laure Pagès   🙏 Merci tout particulièrement aux entreprises qui ont répondu à l'enquête : Ai-biopharma, AQEMIA, Cure51, DeepLife, MAbSilico, Mnemo Therapeutics, Okomera, One Biosciences, Orakl Oncology, Qubit Pharmaceuticals, Rosetta Omics, Scienta Lab et WhiteLab Genomics

💰 Orakl Oncology lève 11 millions d'euros pour lutter contre les cancers digestifs La startup a conçu un outil visant à accompagner les acteurs de la recherche en oncologie dans la conception des candidats médicaments. Pour Fanny Jaulin, PhD, CEO d’Orakl Oncology, cette levée de fonds menée par Singular, leur permettra d’enrichir leurs équipes commerciales, d’accroître leur collection d’avatars de tumeurs et d’envisager une série A aux Etats-Unis à l’avenir. 🚀

We’re thrilled to partner with Orakl Oncology as they revolutionize oncology drug development. Founded in 2023 by Gustave Ronteix, Diane-Laure Pagès and Fanny Jaulin, PhD, Orakl is tackling one of oncology’s biggest challenges: only 4% of cancer drug candidates reach patients. Why? Inaccurate and disjointed decisions made from heterogeneous data and models that do not translate well in humans. Orakl’s groundbreaking AI-powered techbio platform changes the game. Their “patient avatars” integrate real-world data and advanced biology to simulate real-life drug responses. This means: - Better clinical trial predictions - Faster identification of effective treatments - Higher probability of success for new therapies What sets Orakl apart is its cutting-edge technology and exceptional founding team—combining deep expertise in cancer research, cell biology and computational biology. We’re proud to lead their €11M Seed round and can’t wait to see how they continue to drive meaningful progress in oncology. More here 👉 https://lnkd.in/d9ZK22kf

🚀  Orakl Oncology is thrilled to announce a seed round of €11 million to launch first-in-class AI-powered drug development products for biopharma and biotech ✨ We raised €11 million in seed funding, led by Singular. This investment follows a €3M pre-seed round in October 2023 led by Speedinvest with participation from HCVC and Verve Ventures. This funding will fuel the development of Orakl’s business unit and prepare the company for strategic collaborations with pharmaceutical partners. To lead this initiative, we have appointed Jessica Atkinson (FMI, Merck) as Business Advisor and opened a BD director position. We are now marketing our first AI-powered commercial solutions, the first product, O-Predict, forecasts patient responses to new drug candidates, predicting key clinical outcomes such as the number of responders and progression-free survival. 🔮 Our mission at Orakl is to revolutionize drug development by offering an unparalleled decision-making platform that empowers drug developers to de-risk clinical trials and expedite the availability of new transformative medicines. We aim to redefine the future of precision medicine and deliver breakthroughs that patients desperately need. 🙏 We warmly thank our investors and business angels for their continuous support in this mission, as well as Gustave Roussy, our other partners, and our Oraklees for their tremendous contributions. We will be recruiting, stay posted! SISTAFUND, Tatiana Jama Natacha Brami, Jonathan Benhamou, Sébastien Bazin, Paul Bazin, Maximilien Levesque, Mostafa ElSayed, François Morice, Bpifrance Thanks to Les Echos and TechCrunch for their articles about Orakl Oncology, you will find the links in the comment section. cc Fanny Jaulin, PhD, Diane-Laure Pagès, Gustave Ronteix, Jeremy Uzan, Maud Larbey, Andrea Zitna, Estelle Botbol 🎗️, Alexis Houssou, Xavier Mesnier, Fabrice Barlesi, Christophe Javaud

🇯🇵 Come and meet Orakl Oncology at our booth during Hello Tomorrow Japan Deep Tech Summit 2024 in Tokyo this Friday Diane-Laure Pagès, co-founder and COO, will be in Tokyo from Dec 2nd to Dec 6th for both Hello Tomorrow Japan Deept Tech Summit and Innovation Leaders Summit, ''Asia's largest open innovation event'' to meet Japanese and international partners, and present how we transform and accelerate drug development in oncology with our unique patient tumor avatars. Thanks to J. D. F. and Diane D. from Hello Tomorrow Japan for the invitation and coordination! #deeptech #tokyo #innovation #drugdevelopment #oncology

🌟 Join us at the École Polytechnique Forum on November 26-27! Our data team will be represented by Gustave Ronteix, CTO, Jean Bouteiller, Lead Data Scientist, and Lélia Polit, Computational Biologist. We can’t wait to meet students from all programs at l’X or alumnis willing to join the adventure. Orakl is on a mission to revolutionize drug development in oncology by bridging biology and AI. We are a team of passionate and bold people (including a few alumnis!), and we are eager to share exciting opportunities that might be the perfect fit for you. If you’re around and want to connect, please visit us at our stand, we’d love to chat about our mission and vision! 🎤 Jean will also be meeting Polytechnicians on November 26th at 5:30 PM during the career day. Alongside Chiara Régniez, Cyril Voisard, and Gabriel Franz, he’ll be talking about career opportunities in AI and Health—a game-changing field that’s shaping the future. 📍 Where: École Polytechnique, Palaiseau 🗓️ When: November 26-27, 2024 Come say hi, explore career possibilities, and learn more about what we’re up to. 🚀 Let’s connect! #hiring #techbio #drugdevelopment #datascience #computationalbiology

🌎🤝 Orakl Oncology is looking for a Senior Director Business Development! As the company is growing and developing fast, we're seeking a highly-skilled Senior Director Business Development to help drive and accelerate our development with our fantastic CEO Fanny Jaulin, PhD, building partnerships with biopharmas and biotechs in the oncology field. If you're passionate about building meaningful partnerships, having an impact and are eager to join an ambitious healthcare start-up on an exciting journey, this role is for you. Know someone who would be a great fit? Please share this opportunity! https://lnkd.in/gd_6_ScC More information in comment. #businessdevelopment #partnerships #startup #techbio #cancer #healthcare #hiring

🌍 Global Pioneers of Innovation: Meet International Startups at Hello Tomorrow Japan 2024! 🚀 We’re back with more exciting updates for this year’s Hello Tomorrow Japan Deep Tech Summit 2024! 🌐 This summit will bring together the most groundbreaking startups worldwide, each tackling global challenges with deep tech solutions across AI, biotechnology, clean energy, healthcare, and more. At the event, attendees will have the unique chance to connect with these visionary startups face-to-face, gaining insights into the cutting-edge technologies reshaping industries globally. 🌟 Here’s a spotlight on three more incredible startups you’ll meet at the summit: actome (Germany) – Revolutionizing life sciences with precise molecular analysis, Actome’s scPICO technology advances single-cell proteomics, enabling breakthroughs in precision medicine, diagnostics, and drug development. Wildfire Energy (Australia) – Addressing the waste crisis with their MIHG technology, Wildfire Energy transforms waste into clean energy. Their modular systems convert waste into renewable power, hydrogen, and sustainable fuels with net-negative emissions, perfect for remote communities. Orakl Oncology (France) –  Focused on next-gen cancer care, Orakl Oncology leverages biology- and AI-based tech for accelerated drug development and improved clinical trial success, advancing precision medicine and improving outcomes for cancer patients. These are just a few of the pioneering startups you'll get to explore at Hello Tomorrow Japan Deep Tech Summit 2024! 🎟️ Get your ticket now to be part of this transformative event and discover the future of deep tech. We look forward to seeing you there! 👉 https://lnkd.in/gCT3f4hM #DeepTech #AI #CleanEnergy #Biotechnology #Healthcare #Innovation #Startups #HelloTomorrowJapan #TechSummit2024 #FutureOfTech

🎉 𝐑𝐞𝐣𝐨𝐢𝐠𝐧𝐞𝐳-𝐧𝐨𝐮𝐬 𝐩𝐨𝐮𝐫 𝐥'𝐞́𝐯𝐞́𝐧𝐞𝐦𝐞𝐧𝐭 𝐓𝐞𝐜𝐡𝐁𝐢𝐨 𝐅𝐫𝐚𝐧𝐜𝐞 𝟐𝟎𝟐𝟒 ! 🚀Le 20 novembre de 9h à 14h, ne manquez pas TechBio France, un nouvel événement de référence initié par WhiteLab Genomics en partenariat avec France Biotech et son Groupe d’Expertise IA & biodiscovery ainsi que Future4Care, AI for Health et France Deeptech. Cet événement très attendu a pour but de plonger au cœur des défis et opportunités de l’écosystème TechBio, avec une série de tables rondes, des exposés inspirants et un déjeuner networking. 💡 Au programme : - 𝐐𝐮’𝐞𝐬𝐭-𝐜𝐞 𝐪𝐮𝐞 𝐥𝐚 𝐓𝐞𝐜𝐡𝐁𝐢𝐨 ? Une introduction pour mieux comprendre l’utilisation de l’IA pour la découverte de nouveaux médicaments - 𝐋𝐞𝐬 𝐝𝐞́𝐟𝐢𝐬 𝐝𝐞 𝐥𝐚 𝐓𝐞𝐜𝐡𝐁𝐢𝐨 : Un secteur d’avenir et les enjeux qui l’accompagnent. - 𝐅𝐢𝐧𝐚𝐧𝐜𝐞𝐫 𝐥𝐚 𝐫𝐞́𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐓𝐞𝐜𝐡𝐁𝐢𝐨 : Explorer les stratégies et opportunités d’investissement. - 𝐋’𝐈𝐀 « 𝐦𝐚𝐝𝐞 𝐢𝐧 𝐅𝐫𝐚𝐧𝐜𝐞 » 𝐝𝐚𝐧𝐬 𝐥𝐚 𝐝𝐞́𝐜𝐨𝐮𝐯𝐞𝐫𝐭𝐞 𝐝𝐞 𝐦𝐞́𝐝𝐢𝐜𝐚𝐦𝐞𝐧𝐭𝐬 : Rendre la France compétitive à l’échelle mondiale. - 𝐏𝐫𝐞́𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐝'𝐮𝐧𝐞 𝐞́𝐭𝐮𝐝𝐞 𝐞𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐬𝐮𝐫 𝐥𝐞𝐬 𝐬𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐓𝐞𝐜𝐡𝐁𝐢𝐨 𝐟𝐫𝐚𝐧𝐜̧𝐚𝐢𝐬𝐞𝐬 menée par le groupe d’expertise « IA & Biodiscovery » de France Biotech.   🗣️ Frédéric Girard, président de France Biotech interviendra en introduction de cette journée, 🗣️ Un représentant du Groupe d’Expertise IA & Biodiscovery de France Biotech, Antonio V Borderia Giner ADLIN Science présentera les travaux du groupe à travers une cartographie des différents modèles d’affaires TechBio en France, 🗣️ La conférence inclura aussi une table ronde sur le financement de ces modèles, animée par Mathieu Losguardi, co-coordinateur de la commission business développement de France Biotech 📅 Réservez votre place dès maintenant pour rencontrer les acteurs de la TechBio et participer à cette réflexion collective sur l'avenir de la découverte de médicaments en France ! 👉 https://lnkd.in/dUCFsGkk Merci aux membres du GE et WhiteLab Genomics pour cette initiative ! David Del Bourgo Timothé CYNOBER (Pharm D.) Rayhan Ullah Diane-Laure Pagès Caryn Trocmé-Thibierge Fanny Goretta Ai-biopharma AQEMIA Biolevate Bioptimus Cure51 DeepLife EpiGene Generare iktos Insiliance InSiliBio Ksilink MAbSilico Mnemo TherapeuticsOkomera One Biosciences Orakl Oncology Owkin Qubit Pharmaceuticals Rosetta Omics Scienta Lab  

🚀 It’s D-Day !  The ACROConnect Workshop has started this morning at the Maison de la RATP. There are some great presentations  focused on providing innovative solutions that empower research and development in various fields, including organoids, drug screenings and antibody-mediated therapeutics currently going on.    Our Laboratory Head, Jérôme Caron, will present his talk titled “High-throughput drug screenings on colorectal and pancreatic cancerous patient-derived organoids to predict patient responses in the clinic” from 2:05 to 2:35 PM.     Join us and seize the opportunity to connect with us at the Networking Apéro at 5:20 PM, where we can share insights, network, and explore new opportunities together.    📍 Venue: Maison de la RATP, Salle H, Paris, France   🗓 Date: November 12th, 2024   🕣 Time: 8:30 AM - 6:00 PM